Abstract
Annals of the New York Academy of SciencesVolume 886, Issue 1 p. 252-256 Cellular Effects of a New Farnesyltransferase Inhibitor, RPR-115135, in a Human Isogenic Colon Cancer Cell Line Model System HCT-116 P. RUSSO, Corresponding Author P. RUSSO Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, Italy To whom correspondence should be addressed: Department of Experimental Oncology, National Cancer Institute, Largo Rosanna Benzi 10, I-16132 Genoa, Italy. Phone, +39 010 5600212; fax, +39 010 5600210. e-mail, [email protected]Search for more papers by this authorC. OTTOBONI, C. OTTOBONI Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, ItalySearch for more papers by this authorC. FALUGI, C. FALUGI Department of Developing Biology, University of Genoa, Genoa, ItalySearch for more papers by this authorW. REINHOLD, W. REINHOLD Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USASearch for more papers by this authorJ. F. RIOU, J. F. RIOU Anticancer Research Program, Centre de Recherche Rhone-Poulenc Rorer, Vitry F-94403, FranceSearch for more papers by this authorS. PARODI, S. PARODI Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, ItalySearch for more papers by this authorP. M. O'CONNOR, P. M. O'CONNOR Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USASearch for more papers by this author P. RUSSO, Corresponding Author P. RUSSO Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, Italy To whom correspondence should be addressed: Department of Experimental Oncology, National Cancer Institute, Largo Rosanna Benzi 10, I-16132 Genoa, Italy. Phone, +39 010 5600212; fax, +39 010 5600210. e-mail, [email protected]Search for more papers by this authorC. OTTOBONI, C. OTTOBONI Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, ItalySearch for more papers by this authorC. FALUGI, C. FALUGI Department of Developing Biology, University of Genoa, Genoa, ItalySearch for more papers by this authorW. REINHOLD, W. REINHOLD Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USASearch for more papers by this authorJ. F. RIOU, J. F. RIOU Anticancer Research Program, Centre de Recherche Rhone-Poulenc Rorer, Vitry F-94403, FranceSearch for more papers by this authorS. PARODI, S. PARODI Laboratory of Experimental Oncology, National Cancer Institute and Department of Clinical and Experimental Oncology, University of Genoa, Genoa I-16132, ItalySearch for more papers by this authorP. M. O'CONNOR, P. M. O'CONNOR Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USASearch for more papers by this author First published: 06 February 2006 https://doi.org/10.1111/j.1749-6632.1999.tb09429.xCitations: 4 Oncology Research Division, Agouron Pharmaceuticals, Inc., San Diego, CA 92121, USA Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume886, Issue1ANTICANCER MOLECULES: STRUCTURE, FUNCTION, AND DESIGNDecember 1999Pages 252-256 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
